Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

SAMDI Tech’s Dr. Zachary Gurard-Levin Elected to Society of Laboratory Automation and Screening (SLAS) Board

SAMDI Tech, the industry’s leading provider of label-free drug discovery solutions,  announced that Chief Scientific Officer Zachary Gurard-Levin, Ph.D., has been elected to the board of directors for the Society of Laboratory Automation and Screening (SLAS). The board’s diverse group includes leaders from academic, industry and government research, as well as developers and providers of laboratory automation technologies.

Latest NaturalAI Insights: InspireXT Announces Acquisition Of NaturalAI – A Conversational Artificial Intelligence Platform To Expand Its Solution Portfolio

Drug discovery research leader and CSO at SAMDI Tech, Dr. Zachary Gurard-Levin, is one of three experts elected to the Society of Laboratory Automation and Screening (SLAS) Board.

“SLAS has had a significant impact on my scientific growth and development,” Dr. Gurard-Levin said. “I appreciate the society’s power to promote good science and unite researchers from different technical backgrounds and geographic locations. I look forward to providing a fresh perspective to enable and support SLAS’ mission while providing resources for our diverse, international community as we construct the labs of the future.”

Dr. Gurard-Levin is one of three new board members elected who are responsible for strategic leadership of the society and advising on its future direction and its programs. He will begin a three-year term in January 2023.

Related Posts
1 of 33,675

AI News: Darth Vader, Cyber Cartography and the Future of Creativity—Powered by AI

“Dr. Gurard-Levin not only co-developed the SAMDI technology as a high-throughput, label-free solution for drug discovery research, he also brings his in-depth broad scientific and business expertise to the board,” said SAMDI Tech CEO Emilio Cordova, Ph.D. “He brings a unique voice to the board for all members — from young scientists to experienced executives — to support innovation across the fields of life and health sciences.”

SAMDI Tech, Inc. delivers better, faster assay development, high-throughput screening and hit-to-lead solutions for early-stage drug discovery. Our highly skilled team of biochemistry experts believes in quality results and uses proprietary industry-leading, label-free SAMDI (Self-Assembled Monolayer Desorption Ionization) technology to deliver decision-making data for diverse targets and analytes.

The Natural Language Processing Techniques : The Electronic Medical Records Market Sees A Rising Adoption Of The Natural Language Processing Techniques By The Business Research Company

 [To share your insights with us, please write to sghosh@martechseries.com] 

Comments are closed.